Skip Navigation


Annals of Oncology Advance Access originally published online on September 9, 2007
Annals of Oncology 2008 19(2):292-298; doi:10.1093/annonc/mdm438
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/2/292    most recent
mdm438v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by von Minckwitz, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by von Minckwitz, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology. For Permissions, please email: journals.permissions@oxfordjournals.org

breast cancer

Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study

G. von Minckwitz1,15,*, S. Kümmel2,3, A. du Bois4, W. Eiermann5, H. Eidtmann6, B. Gerber7, J. Hilfrich8, J. Huober9, S. D. Costa10, C. Jackisch11, S.-T. Grasshoff12, S. Vescia1, T. Skacel13,14, S. Loibl1,15, K. M. Mehta1, M. Kaufmann15 and On behalf of the German Breast Group

1 German Breast Group, Neu-Isenburg
2 Universitäts-Frauenklinik, Charité, Berlin
3 Universitäts-Frauenklinik, Essen
4 Dr Horst-Schmidt-Klinik, Wiesbaden, Frauenklinik
5 Frauenklinik vom Roten Kreuz, Munich
6 Universitäts-Frauenklinik, Kiel
7 Universitäts-Frauenklinik Rostock
8 Henrietten Stift, Hannover, Frauenklinik
9 Universitäts-Frauenklinik, Tübingen
10 Universitäts-Frauenklinik, Magdeburg
11 Klinik für Gynäkologie und Geburtshilfe, Offenbach, Frauenklinik
12 Frauenklinik, Quedlinburg, Germany
13 Amgen (Europe) GmbH, Lucerne, Switzerland
14 Department of Internal Medicine–Hematoonkology, University Hospital, Brno, Czech Republic
15 Universitäts-Frauenklinik, Frankfurt, Germany

* Correspondence to: Dr G. von Minckwitz, German Breast Group/Universitäts-Frauenklinik Frankfurt, Schleussner Str. 42, 63263 Neu-Isenburg, Germany. Tel: +49-6102-798740; Fax:+49-6102-7987440; E-mail: minckwitz{at}germanbreastgroup.de

Background: TAC (docetaxel/doxorubicin/cyclophosphamide) is associated with high incidences of grade 4 neutropenia and febrile neutropenia (FN). This analysis compared the efficacies of four regimens for primary prophylaxis of FN and related toxic effects in breast cancer patients receiving neoadjuvant TAC.

Patients and methods: Patients with stage T2–T4 primary breast cancer were scheduled to receive 6–8 cycles of TAC. Primary prophylaxis was: ciprofloxacin 500 mg orally twice daily on days 5–14 (n = 253 patients; 1478 cycles), daily granulocyte colony-stimulating factor (G-CSF) (filgrastim 5 µg/kg/day or lenograstim 150 µg/m2/day) on days 5–10 (n = 377; 2400 cycles), pegfilgrastim 6 mg on day 2 (n = 305; 1930 cycles), or pegfilgrastim plus ciprofloxacin (n = 321; 1890 cycles).

Results: Pegfilgrastim with/without ciprofloxacin was significantly more effective than daily G-CSF or ciprofloxacin in preventing FN (5% and 7% versus 18% and 22% of patients; all P < 0.001), grade 4 neutropenia, and leukopenia. Pegfilgrastim plus ciprofloxacin completely prevented first cycle FN (P < 0.01 versus pegfilgrastim alone) and fatal neutropenic events.

Conclusion: Ciprofloxacin alone, or daily G-CSF from day 5–10 (as in common practice), provided suboptimal protection against FN and related toxic effects in patients receiving TAC. Pegfilgrastim was significantly more effective in this setting, especially if given with ciprofloxacin.

Key words: breast cancer, ciprofloxacin, docetaxel, febrile neutropenia, granulocyte colony-stimulating factor, primary prophylaxis

Received for publication April 3, 2007. Revision received August 1, 2007. Accepted for publication August 7, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.